Organon (OGN) | Stock Overview & Key Data

What is OGN's 52-week high and low?

In the last 52 weeks, Organon reached a high of $23.10 (on August 26, 2024) and a low of $8.01 (on May 14, 2025).

What is the market cap and P/E ratio for OGN?

Curious about Organon's size and valuation? Its market capitalization stands at 2.53B. When it comes to valuation, the P/E ratio (trailing twelve months) is 3.39, and the forward P/E (looking ahead) is 2.30.

Does OGN pay dividends? If so, what's the yield?

Yes, Organon is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 8.50%, and the company has paid an average of $1.03 per share annually over the past 3 years.

Who are Organon's main competitors or similar companies to consider before investing?

When looking at Organon, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Eli Lilly and LLY	691.83B	Healthcare	Drug Manufacturers - General	-14.64%	136.23%
Johnson & Johnson JNJ	364.09B	Healthcare	Drug Manufacturers - General	6.51%	-12.49%
AbbVie ABBV	324.59B	Healthcare	Drug Manufacturers - General	13.17%	23.83%
Merck & Co MRK	198.52B	Healthcare	Drug Manufacturers - General	-36.00%	-12.77%
Amgen AMGN	146.49B	Healthcare	Drug Manufacturers - General	-4.07%	20.03%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Organon & Co.? (e.g., ROE, Debt/Equity)

To get a sense of Organon's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 254.24%, the Debt to Equity ratio from the most recent quarter is 1,652.40, and its Gross Profit Margin stands at 55.58%.

What is the recent revenue and earnings growth for OGN?

Looking at Organon's growth, its revenue over the trailing twelve months (TTM) was $6B. Compared to the same quarter last year (YoY), quarterly revenue grew by -6.70%, and quarterly earnings saw a YoY growth of -56.70%.

How much of OGN stock is held by insiders and institutions?

Wondering who owns Organon stock? Company insiders (like executives and directors) hold about 0.24% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.92%.

For more common questions about our data, please visit our About Data page.